CareDx, Inc.

235 articles with CareDx, Inc.

• CareDx to Participate at the Canaccord Genuity 40th Annual Growth Conference

  7/30/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020.

• CareDx to Report Second Quarter 2020 Financial Results

  7/16/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it will release financial results for the second quarter 2020 after the close of trading on Tuesday, August 4, 2020.

• CareDx Chairman and CEO Peter Maag to Present at Global Kidney Innovations SummitPeter Maag is Presenting on AI in Transplant Care at the AAKP and George Washington International Patient Summit

  7/15/2020

  CareDx, Inc. announces that Peter Maag, Chairman and CEO of CareDx, will present at a panel hosted by the American Association of Kidney Patients and the George Washington University School of Medicine and Health Sciences on “Emerging Innovation in Kidney Disease with Global Implications: Artificial Intelligence in Transplant Care.” The summit is scheduled to be held from July 16 to July 17, 2020.

• New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of ChoiceHead to head data shows that not all dd-cfDNA is the same

  6/22/2020

  CareDx, Inc. announces that the journal of the American Society of Nephrology, Kidney360, published a study evaluating AlloSure simultaneously with a different donor-derived cell-free DNA monitoring tool for allograft rejection.

• FDA Accepts Letter of Intent for iBox Scoring System as a Surrogate Endpoint in Pharmaceutical Clinical Trials

  6/18/2020

  CareDx congratulates C-Path’s Transplant Therapeutics Consortium on utilizing iBox to streamline the development of novel transplant drugs

• CareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

  6/18/2020

  CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 585,937 shares of common stock

• CareDx Announces Closing of Public Offering of Common Stock - June 15, 2020

  6/15/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the closing of its previously announced public offering of 3,906,250 shares of its common stock at a public offering price of $32.00 per share.

• CareDx Announces Pricing of Public Offering of Common Stock - June 11, 2020

  6/11/2020

  CareDx, Inc. announced the pricing of an underwritten public offering of 3,906,250 shares of its common stock at a public offering price of $32.00 per share.

• Seven Bridges Selected by CareDx to Advance Its Transplant Care Solutions

  6/9/2020

  The Seven Bridges Bioinformatics Ecosystem Supports the Critical Turnaround Times for the CareDx AlloSure® 3.0 Workflow

• CareDx Announces Proposed Public Offering of Common Stock - June 09, 2020

  6/9/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it intends to offer and sell, subject to market and other conditions, up to $100.0 million of shares of its common stock in an underwritten public offering.

• CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting

  6/8/2020

  CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a change to its 2020 Annual Meeting of Stockholders

• CareDx to Participate at the Goldman Sachs Global Healthcare Conference

  6/4/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the company will be participating in the upcoming Goldman Sachs Global Healthcare Conference.

• CareDx to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/28/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference.

• CareDx Presents the Latest AlloSure Data in Virtual MeetingsLeading transplant clinicians to present ten abstracts accepted for presentation at the American Transplant Congress

  5/27/2020

  CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the delivery of content on state-of-the-art research accepted at the American Transplant Congress (ATC) annual meeting scheduled for May 30-June 1, 2020. CareDx’s program will include two v

• CareDx's AlloSeq Tx 17 Awarded CE Mark ApprovalCE Mark approval enables global availability of innovative Hybrid-Capture Technology HLA testing for transplant patients

  5/15/2020

  CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it had received the CE mark approval for AlloSeq Tx 17, making it broadly available to transplant patients, laboratories and clinicians around the world. AlloSeq Tx 17 is the best in class so

• CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System

  5/14/2020

  CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter® FLEX Analysis System, Veracyte’s diagnostic platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2020051400

• CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMapUroMap Gene Expression Test Will Add to CareDx’s Best In Class Transplant Surveillance Comprehensive Solutions

  5/5/2020

  CareDx, Inc. announced a strategic alliance with Weill Cornell Medicine that makes CareDx the exclusive development and commercialization partner of UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

• CareDx Reports First Quarter 2020 Results

  4/30/2020

  CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, reported financial results for the quarter ended March 31, 2020.

• CareDx Engages European Lab Community in Virtual MeetingsLeaders in HLA and transplant laboratory solutions will present at CareDx virtual symposiums originally planned for EFI

  4/27/2020

  CareDx, Inc. announced the online delivery of the content originally meant for showcase at the now-postponed annual European Immunogenetics and Histocompatibility Conference that was scheduled for Apr 26-29, 2020 in Glasgow, Scotland.

• CareDx and Johns Hopkins Partner on AlloSure Lung Surveillance

  4/23/2020

  CareDx and Johns Hopkins Announce Mobile Health Partnership with RemoTraC Use Among Lung Transplant Patients